Cambridge Heart Inc. is looking yet again to find a way to make its core Microvolt T-Wave Alternans technology pay.
The Tewksbury, Mass.-based cardiac monitor maker said preliminary data shows that a variant of its MTWA spectral analytic method of measuring alternans, or variations in the amplitude of the T wave in an electrocardiogram, could be used to detect myocardial ischemia.
That’s when blocked or partially occluded blood vessels limit blood supply to heart muscles; the condition can lead to myocardial infarctions, otherwise known as heart attacks.
CEO Ali Haghighi-Mood said an examination of preliminary data indicates that a positive alternans reading corresponded with myocardial ischemia, which traditional cardiac stress tests missed.
Cambridge Heart said it filed a provisional patent on the application and plans to file for a full patent by the end of the year. It’s also designing a pilot study, which it hopes to begin during the first half of next year.
It’s not the first time the company has sought to reinvent itself. In June, Cambridge Heart said it planned to shift gears and market an OEM version of MTWA test to other manufacturers.
Cambridge Heart posted a second-quarter net loss of $1.8 million on sales of $793,000, compared with a net loss of $2.6 million on sales of $927,000 during the same period last year.